Triple negative/HER2+/≥4 lymph nodes: 18F FDG PET/CT + CTX every 6 months, bone metastasis patients: DCE MRI every 3 months (distinguishes efficacy vs. pseudoprogression). This evidence concerns the gene ERBB2 and bone metastasis.